Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Operating Income Growth Recovery in ProgressRecovering
Percentile Rank54
5Y CAGR-2.5%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-2.5%/yr
Long-term compound
Percentile
P54
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 9.63% |
| Q3 2025 | 3.05% |
| Q2 2025 | 82.69% |
| Q1 2025 | -38.59% |
| Q4 2024 | -8.09% |
| Q3 2024 | 131.76% |
| Q2 2024 | -408.44% |
| Q1 2024 | 15.28% |
| Q4 2023 | -4.78% |
| Q3 2023 | 1.14% |
| Q2 2023 | 31.76% |
| Q1 2023 | -24.63% |
| Q4 2022 | -8.27% |
| Q3 2022 | 1.84% |
| Q2 2022 | 6.28% |
| Q1 2022 | 18.59% |
| Q4 2021 | -16.77% |
| Q3 2021 | 2882.35% |
| Q2 2021 | -104.27% |
| Q1 2021 | 19.04% |
| Q4 2020 | 10.94% |
| Q3 2020 | -6.38% |
| Q2 2020 | -0.30% |
| Q1 2020 | 30.60% |
| Q4 2019 | 455.17% |
| Q3 2019 | -63.20% |
| Q2 2019 | -2.47% |
| Q1 2019 | 116.73% |
| Q4 2018 | -37.89% |
| Q3 2018 | 18.96% |
| Q2 2018 | 34.12% |
| Q1 2018 | 2.52% |
| Q4 2017 | 138.56% |
| Q3 2017 | -718.60% |
| Q2 2017 | -80.54% |
| Q1 2017 | 583.25% |
| Q4 2016 | 282.45% |
| Q3 2016 | -747.99% |
| Q2 2016 | 123.40% |
| Q1 2016 | 74.17% |